CLAIMS

1. A pharmaceutical composition comprising a chemotherapeutic drug and a netrin-1 interfering drug or a vector capable of expressing a netrin-1 interfering drug *in vivo*, in a pharmaceutically acceptable carrier or vehicle, for use as a medicament for treating a cancer expressing or over-expressing netrin-1.

2. The composition for the use according to claim 1, wherein the netrin-1 interfering drug promotes netrin-1 receptors-induced apoptosis.

3. The composition for the use according to claim 2, wherein the netrin-1 interfering drug is an antibody binding to netrin-1 or to a netrin-1 receptor.

4. The composition for the use according to claim 2, wherein the netrin-1 interfering drug is a compound comprising an extracellular domain of a netrin-1 receptor or a fragment of said extracellular domain.

5. The composition for the use according to claim 2, wherein the netrin-1 interfering drug is a compound comprising an extracellular domain of a netrin-1 receptor DCC, UNC5A, UNC5B, UNC5C or UNC5D or a fragment of said extracellular domain.

6. The composition for the use according to claim 4 or 5, wherein the netrin-1 interfering drug is a fusion protein comprising an extracellular domain of a netrin-1 receptor or fragment thereof and an antibody Fc part.

7. The composition for the use according to claim 2, wherein the netrin-1 interfering drug is a compound comprising a peptidic moiety, which is able to bind to a netrin-1 receptor, this binding being able to prevent netrin-1 ability to block apoptosis induction by a netrin-1 receptor.

8. The composition for the use according to claim 2, wherein the netrin-1 interfering drug is a siRNA which reduces expression of the gene coding for netrin-1.

9. The composition for the use according to any one of the preceding claims, wherein the chemotherapeutic drug is a drug which is able to induce an over-expression of netrin-1 in cancer cells.

10. The composition for the use according to claim 9, wherein the chemotherapeutic drug is doxorubicin, 5-fluorouracil (5FU), paclitaxel, or cisplatin.

11. A pharmaceutical composition comprising a chemotherapeutic drug which is able to induce an over-expression of netrin-1 in cancer cells, for use as an anti-cancer medicament to be used in a patient in combination with a netrin-1 interfering drug or a vector

capable of expressing a netrin-1 interfering drug *in vivo*, to treat a cancer expressing or over-expressing netrin-1.

12. The composition for the use according to any one of the preceding claims, comprising a chemotherapeutic drug and a netrin-1 interfering drug or a vector capable of expressing a netrin-1 interfering drug *in vivo*, for a simultaneous, separate or sequential administration to a patient.

13. A method for treating a cancer expressing or overexpressing netrin-1, wherein an efficient amount of a chemotherapeutic drug and of a netrin-1 interfering drug or a vector capable of expressing a netrin-1 interfering drug *in vivo*, in a pharmaceutically acceptable carrier or vehicle, is administered to a patient in need thereof.

CLAIMS

1. A pharmaceutical composition comprising a chemotherapeutic drug and a netrin-1 interfering drug or a vector capable of expressing a netrin-1 interfering drug *in vivo*, in a pharmaceutically acceptable carrier or vehicle, when used for treating a cancer expressing or over-expressing netrin-1.

2. The composition according to claim 1, wherein the netrin-1 interfering drug promotes netrin-1 receptors-induced apoptosis.

3. The composition according to claim 2, wherein the netrin-1 interfering drug is an antibody binding to netrin-1 or to a netrin-1 receptor.

4. The composition according to claim 2, wherein the netrin-1 interfering drug is a compound comprising an extracellular domain of a netrin-1 receptor or a fragment of said extracellular domain.

5. The composition according to claim 2, wherein the netrin-1 interfering drug is a compound comprising an extracellular domain of a netrin-1 receptor DCC, UNC5A, UNC5B, UNC5C or UNC5D or a fragment of said extracellular domain.

6. The composition according to claim 4 or 5, wherein the netrin-1 interfering drug is a fusion protein comprising an extracellular domain of a netrin-1 receptor or fragment thereof and an antibody Fc part.

7. The composition according to claim 2, wherein the netrin-1 interfering drug is a compound comprising a peptidic moiety, which is able to bind to a netrin-1 receptor, this binding being able to prevent netrin-1 ability to block apoptosis induction by a netrin-1 receptor.

8. The composition according to claim 2, wherein the netrin-1 interfering drug is a siRNA which reduces expression of the gene coding for netrin-1.

9. The composition according to any one of the preceding claims, wherein the chemotherapeutic drug is a drug which is able to induce an over-expression of netrin-1 in cancer cells.

10. The composition according to claim 9, wherein the chemotherapeutic drug is doxorubicin, 5-fluorouracil (5FU), paclitaxel, or cisplatin.

11. A pharmaceutical composition comprising a chemotherapeutic drug which is able to induce an over-expression of netrin-1 in cancer cells, when used as an anti-cancer medicament in a patient in combination with a netrin-1 interfering drug or a vector capable of

expressing a netrin-1 interfering drug *in vivo*, to treat a cancer expressing or over-expressing netrin-1.

12. The composition according to any one of the preceding claims, comprising a chemotherapeutic drug and a netrin-1 interfering drug or a vector capable of expressing a netrin-1 interfering drug *in vivo*, for a simultaneous, separate or sequential administration to a patient.

13. A method for treating a cancer expressing or overexpressing netrin-1, wherein an efficient amount of a chemotherapeutic drug and of a netrin-1 interfering drug or a vector capable of expressing a netrin-1 interfering drug *in vivo*, in a pharmaceutically acceptable carrier or vehicle, is administered to a patient in need thereof.